# Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

> **NCT04575415** · — · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 272 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **DRUG:** Gefitinib
- **DRUG:** Icotinib
- **DRUG:** Afatinib
- **DRUG:** Dacomitinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04575415
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-07
- **Primary completion:** 2023-05
- **Final completion:** 2023-12
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575415, "Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04575415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*